ArticlePloS one2026
Al18F-NOTA-FAPI-04 PET/CT for diagnosis of breast cancer and its correlation with pathological features: A single-center retrospective study.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo systematically evaluate the diagnostic efficacy of Al¹⁸F-NOTA-FAPI-04 PET/CT in breast cancer and explore the correlation between tracer uptake parameters and pathological features of breast cancer based on single-centre, retrospective data.
methodsThis single-center retrospective study enrolled 58 female patients with suspected primary breast cancer who underwent Al¹⁸F-NOTA-FAPI-04 PET/CT before surgery or core needle biopsy (February 2023-November 2025). Lesion maximum/mean standardized uptake values (SUVmax/SUVmean) were measured via region-of-interest analysis. Semi-quantitative positivity thresholds (SUVmax > 2.5 or tumor-to-background ratio ≥ 1.5) were used for lesion classification. Diagnostic efficacy (sensitivity, specificity, accuracy) was calculated with pathological results as the gold standard, and 95% confidence intervals (CIs) were determined via the Clopper-Pearson exact method. Differences in uptake parameters across pathological types, molecular subtypes, and immunohistochemical (ER/PR/HER2/Ki-67) statuses were analyzed using Mann-Whitney U or Kruskal-Wallis H tests.
resultsOf 58 patients, 49 had breast cancer and 9 had benign lesions. Al¹⁸F-NOTA-FAPI-04 PET/CT achieved a sensitivity of 95.9% (95% CI: 86.3%-99.5%), specificity of 88.9% (95% CI: 51.9%-99.7%), and accuracy of 94.8% (95% CI: 85.8%-98.9%). All 53 primary lesions were detected (detection rate: 100%), and the detection rate for 87 lymph node metastases was 96.5%. SUVmax/SUVmean of malignant lesions (median [IQR]: 13.20 [9.55-17.85]/8.15 [5.68-10.92]) were significantly higher than those of benign lesions (2.13 [1.56-2.89]/1.35 [0.98-1.86], both P < 0.001). No statistically significant differences in uptake parameters were observed across pathological types, molecular subtypes, or ER/PR/HER2/Ki-67 statuses (all P > 0.05), though numerical trends existed; this may be attributed to Type II error due to small subgroup sizes and insufficient statistical power (29.7%-62.3% for detecting medium-to-large effect sizes). No correlation was found between lesion size and uptake parameters (r = 0.186 for SUVmax, r = 0.165 for SUVmean, both P > 0.05).
conclusionAl¹⁸F-NOTA-FAPI-04 PET/CT exhibits high sensitivity and accuracy for breast cancer diagnosis and lymph node metastasis detection, with uptake independent of blood glucose levels. Its core clinical roles include complementary initial diagnosis in high-risk subgroups (dense breasts, diabetes), primary nodal staging, and problem-solving in equivocal cases. However, the lack of significant correlation between uptake parameters and pathological features should be interpreted cautiously due to potential Type II error. These characteristics make it a versatile imaging tool for breast cancer diagnosis and staging in regional tertiary care settings, with further validation needed in larger, balanced cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.